Skip to main content
Premium Trial:

Request an Annual Quote

IP Landscape -- Rundown for Key RNAi Drug Developers

IP Landscape — Rundown for Key RNAi Drug Developers
IP Overview
Key IP
Alnylam Pharmaceuticals
According to Alnylam, the company has rights on more than 150 issued patents and patent applications worldwide covering the synthetic chemistry used in the discovery, development, and commercialization of therapeutic RNAi molecules. The company also claims exclusive rights to patents and applications related to the structure and function of siRNAs and their use as human drugs. The company also says it has licensed or filed patent applications covering more than 200 disease targets.

EP 1144623 (Kreutzer-Limmer patent) — This patent covers methods and medicaments involving the use of small dsRNA formed from two separate strands and having a region complementary to the target gene of not more than 25 nucleotide pairs.

WO 02/44321 (Tuschl-2 patent application) — This patent application describes RNAi using siRNAs with two-to-three nucleotide 3' overhangs on the end.

US 5,898,031 and US 6,107,094 (Crooke patents) — These patents, which Alnylam licensed from Isis Pharmaceuticals, cover degradation of target mRNA mediated by chemically modified RNAi-like oligonucleotides.

According to Benitec, the company has one issued US patent and 11 issued foreign patents. Additionally, the company has rights to 42 patent applications worldwide, and has exclusively in-licensed two US patents and three foreign patent applications.

US 6,573,099 — This patent covers the knocking down of gene expression in plants, as well as animals, using DNA that transcribes double-stranded RNA, one strand of which has a sequence complementary to that of the target gene.

US 20050197313 — This patent application covers multiple-promoter expression cassettes for simultaneous delivery of RNAi, including to mammalian cells in vivo.

US 20030153519 — This patent application covers the use of an RNAi agent such as an siRNA or shRNA for modulating coding sequence expression in mammals.

Nucleonics says it has rights to 19 distinct RNAi-related patent families, 11 of which are Nucleonics owned; the other eight have be in-licensed. These pieces of IP, the company says, are directed to a variety of aspects of RNAi including dsRNA-mediated gene silencing, RNAi-based functional genomics methods, compositions and methods for nucleic acid delivery, manufacturing methods, and RNAi-based drug targets.

US 20020114784 — This patent application covers the introduction of dsRNA into cells, cell culture, organs, tissues, and whole organisms, particularly vertebrates, to attenuate gene expression.

US 5,624,803 — This patent covers methods and materials for delivering antisense, triplex, and/or ribozyme oligonucleotides intracellularly, as well as RNA polymerase III-based constructs to accomplish delivery.

US 20040147476 — This patent application covers a therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell with a an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length and substantially homologous to a target polynucleotide sequence.

Sirna Therapeutics
Sirna says its IP estate — which includes 48 issued patents and 250 patent applications worldwide — covers all aspects of drug design, synthesis, development, and manufacturing. Its IP, the company says, covers such areas as chemically modified siRNAs and siNAs, multifunctional siRNAs, microRNAs, drug targets, and delivery methods.

WO 01/75164 — (Tuschl-1 patent application) — This patent application covers the use of short interfering RNAs, 21 to 23 nucleotides in length, to induce RNAi in mammalian cells.

GB 2396616 — This patent covers small nucleic acid molecules, such as siRNAs, capable of mediating RNAi against target nucleic acid sequences.

GB 2396864 — This patent covers the use of small nucleic acid molecules, such as siRNAs, to mediate RNAi against vascular endothelial growth factor and vascular endothelial growth factor receptors.

SR Pharma
SR Pharma says that, following its acquisition of Atugen, its IP estate includes 52 patent applications covering RNAi, chemically modified and stabilized siRNAs, cancer targets, and target identification processes.

WO 2004/015107 — This patent application covers blunt-ended forms of siRNAs.

WO 2005/105152 — This patent application covers cationic lipids and related compositions for use in delivering siRNAs.

WO 2004019973 — This patent application covers molecular targets and functional nucleic acids, such as siRNAs, that can be generated against them.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.